Released Feb 26, 2026, after the close
10-K filed Feb 26, 2026, 57 days after period end · 0001628280-26-012352
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$62.14M$62.14M derived+8.1% vs Q4 2024+18.8% vs Q3 2025
Net Income-$44.08M-$44.08M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$32,885,000−2.3%
Operating Incomederived-$5,593,000N/M
Operating Cash Flowderived-$771,000N/M
Free Cash Flowderived-$1,772,000N/M
Margins · derived
Gross margin52.9%−5.6 pt vs Q4 2024
Operating margin-9.0%−14.2 pt vs Q4 2024
Net margin-70.9%−87.7 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $62.14M | $57.48M | $58.23M | $48.34M |
| Net Income | -$44.08M | $9.64M | $5.50M | $3.72M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR